Head-to-head evidence
bimekizumab vs ORKA-002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A/F · full Psoriasis pipeline
bimekizumab · Bimzelx
Marketed by UCB
NCT03370133 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).
Next expected readout: March 2027 · NCT06506916 (registry estimate)
ORKA-002
Developed by Oruka Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07474792 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimekizumab's landscape · ORKA-002's landscape